Enanta Pharmaceuticals, Inc. Reports Financial Results For Its Fiscal Third Quarter Ended June 30, 2016
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal third quarter ended June 30, 2016.
Enanta’s cash, cash equivalents and short-term and long-term marketable securities totaled $244.7 million at June 30, 2016.
Enanta’s cash, cash equivalents and short-term and long-term marketable securities totaled $244.7 million at June 30, 2016.